CureVac (CVAC) said Monday the US Food and Drug Administration has cleared the company to initiate a phase 1 study of its experimental mRNA-based therapy, CVHNLC, in patients with squamous non-small cell lung cancer.
The company said the open-label, dose-finding study will evaluate the safety and tolerability of CVHNLC in combination with pembrolizumab in patients.
The study will include a dose-escalation phase for first-line maintenance treatment following chemotherapy and pembrolizumab or pembrolizumab monotherapy, followed by an optional dose expansion phase combining CVHNLC with first-line chemotherapy and pembrolizumab, the drug developer said.
Shares of the company rose more than 1% in recent premarket activity.
Price: 2.62, Change: +0.03, Percent Change: +1.16
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。